Reaction Details |
| Report a problem with these data |
Target | 5-hydroxytryptamine receptor 1B |
---|
Ligand | BDBM50068818 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_1344 (CHEMBL616529) |
---|
Ki | 2645±n/a nM |
---|
Citation | Nagarathnam, D; Wetzel, JM; Miao, SW; Marzabadi, MR; Chiu, G; Wong, WC; Hong, X; Fang, J; Forray, C; Branchek, TA; Heydorn, WE; Chang, RS; Broten, T; Schorn, TW; Gluchowski, C Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia. J Med Chem41:5320-33 (1999) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
5-hydroxytryptamine receptor 1B |
---|
Name: | 5-hydroxytryptamine receptor 1B |
Synonyms: | 5-HT-1B | 5-HT-1D-beta | 5-HT1B | 5-hydroxytryptamine receptor 1B (5-HT1B) | 5HT1B_HUMAN | HTR1B | HTR1DB | S12 | Serotonin (5-HT) receptor | Serotonin 1D beta receptor | Serotonin Receptor 1B |
Type: | G Protein-Coupled Receptor (GPCR) |
Mol. Mass.: | 43579.17 |
Organism: | Homo sapiens (Human) |
Description: | Receptor binding assays were performed using human clone stably expressed in CHO cells |
Residue: | 390 |
Sequence: | MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKVLLVMLLALIT
LATTLSNAFVIATVYRTRKLHTPANYLIASLAVTDLLVSILVMPISTMYTVTGRWTLGQV
VCDFWLSSDITCCTASILHLCVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWVFSISI
SLPPFFWRQAKAEEEVSECVVNTDHILYTVYSTVGAFYFPTLLLIALYGRIYVEARSRIL
KQTPNRTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSESGSPVYVNQVKVRVSDALLE
KKKLMAARERKATKTLGIILGAFIVCWLPFFIISLVMPICKDACWFHLAIFDFFTWLGYL
NSLINPIIYTMSNEDFKQAFHKLIRFKCTS
|
|
|
BDBM50068818 |
---|
n/a |
---|
Name | BDBM50068818 |
Synonyms: | 1-(3-{[2,6-Dimethyl-5-methylcarbamoyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3-carbonyl]-amino}-propyl)-4-phenyl-piperidine-4-carboxylic acid methyl ester | CHEMBL147077 |
Type | Small organic molecule |
Emp. Form. | C32H39N5O6 |
Mol. Mass. | 589.682 |
SMILES | CNC(=O)C1C(C(C(=O)NCCCN2CCC(CC2)(C(=O)OC)c2ccccc2)=C(C)N=C1C)c1ccc(cc1)[N+]([O-])=O |c:33,t:30| |
Structure |
|